Lucid Diagnostics Q4 2025 revenue $1.5M, net loss $16.3M; VA contract awarded

Lucid Diagnostics Inc.

Q4 EsoGuard tests 3,664; revenue $1.5M; GAAP net loss $16.3M ($0.12/share); non-GAAP adj. loss $12.6M ($0.10/share).
Cash $34.7M at Dec 31, 2025 vs $22.4M at Dec 31, 2024; operating expenses $15.5M incl $1.2M stock-based comp.
Awarded U.S. Department of Veterans Affairs contract for EsoGuard with $1,938 Medicare-aligned pricing across 170 VA medical centers.
Largest real-world esophageal precancer detection study (nearly 12,000 patients) shows EsoCheck 95% technical success rate and 95% procedures under two minutes.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Lucid Diagnostics Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue $1.5 million, net income approximately $16.3 million or $(0.12) per common share, EPS $(0.12) per common share.

Period: fourth quarter and full year ended December 31, 2025
Revenue: $1.5 million
Net income: approximately $16.3 million or $(0.12) per common share
EPS: $(0.12) per common share
Result: reported results

Exact text from the filing

--- Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Processed 3,664 EsoGuard ® tests and recognized 4Q25 revenue of $1.5 million Expanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Lucid Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-012807

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.